After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...

An Institute for Value-Based Medicine ® event held in New Haven, Connecticut, on October 30, 2025, brought together a diverse ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Once largely a diagnosis of exclusion, new tools and treatments are unraveling some of the mysteries surrounding heart failure with preserved ejection fraction.

A large Scandinavian study reopens the debate on beta-blockers after myocardial infarction, revealing selective benefits.

Researchers sought to assess clinical outcomes, prevalence, and 1-year outcomes associated with polypharmacy in patients with heart failure.

This case report describes a woman in her late 50s with reversible pulmonary hypertension (PH) due to scurvy, a rare vitamin ...

Panelists considered the technology relatively safe but weren’t swayed by the “statistical gymnastics” needed to find a ...

The outside advisors analyzed the results of the RELIEVE-HF pivotal trial, which randomized 508 patients to either receive ...

An FDA advisory panel unanimously agreed that Johnson & Johnson MedTech's V-Wave Ventura interatrial shunt's risks outweigh ...

A month has gone by since the last earnings report for Cytokinetics (CYTK). Shares have added about 10.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.